# Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

> **NCT07647263** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 124 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** THP Regimen (Taxane + Trastuzumab + Pertuzumab)
- **DRUG:** Trastuzumab Rezetecan (SHR-A1811)

## Key facts

- **NCT ID:** NCT07647263
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2029-06
- **Final completion:** 2031-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647263, "Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*